UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  SCHEDULE 13G

                    UNDER THE SECURITIES EXCHANGE ACT OF 1934
                               (AMENDMENT NO. 3)*


                         Biospecifics Technologies Corp.
          ------------------------------------------------------------
                                (Name of Issuer)


                          Common Stock, $.001 par value
          ------------------------------------------------------------
                         (Title of Class of Securities)


                                    090931106
                            ------------------------
                                 (CUSIP Number)


                                Jeffrey K. Vogel
                                 Bio Partners LP
                                 1 Meadow Drive
                            Lawrence, New York 11559
                            Telephone: (516) 295-1762
          ------------------------------------------------------------
          (Name, Address and Telephone Number of Persons Authorized to
                       Receive Notices and Communications)


                                December 31, 2006
          ------------------------------------------------------------
             (Date of Event which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this is filed:

[ ]  Rule 13d-1(b)
[X]  Rule 13d-1(c)
[ ]  Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).




                                  SCHEDULE 13G

-------------------------                                 ----------------------
CUSIP No. 090931106                                         Page 2 of 11 Pages
-------------------------                                 ----------------------
--------------------------------------------------------------------------------
1    NAME OF REPORTING PERSON:           Bio Partners LP
     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: [__________________]

--------------------------------------------------------------------------------
2    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a) [ ]
     (b) [ ]
--------------------------------------------------------------------------------
3    SEC USE ONLY

--------------------------------------------------------------------------------
4    CITIZENSHIP OR PLACE OR ORGANIZATION

     Delaware
--------------------------------------------------------------------------------

NUMBER OF SHARES             5    SOLE VOTING POWER           0
BENEFICIALLY OWNED           ---------------------------------------------------
BY EACH REPORTING            6    SHARED VOTING POWER         295,312(1)
PERSON WITH                  ---------------------------------------------------
                             7    SOLE DISPOSITIVE POWER      0
                             ---------------------------------------------------
                             8    SHARED DISPOSITIVE POWER    295,312(1)
--------------------------------------------------------------------------------
9    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     295,312(1)
--------------------------------------------------------------------------------
10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     (See Instructions)         N/A
--------------------------------------------------------------------------------
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     5.3% (2)
--------------------------------------------------------------------------------
12   TYPE OF REPORTING PERSON  (See Instructions)

     PN
--------------------------------------------------------------------------------

(1)  Bio Partners LP, a Delaware limited partnership, has a sole general
     partner, Bio Management, Inc., a New York corporation ("Bio Management"),
     and Bio Management's sole shareholder and President is Jeffrey K. Vogel.
     Mr. Vogel thus has the power to vote or dispose of the 295,312 shares of
     common stock, $.001 par value ("Common Stock") of Biospecifics Technologies
     Corp. ("Biospecifics") owned by Bio Partners LP.

(2)  Calculated based on 5,535,216 shares of Biospecifics Technologies Corp.'s
     Common Stock outstanding as of November 9, 2005, as reported in its proxy
     statement on Schedule 14A filed with the Securities and Exchange Commission
     on December 2, 2005.

                                       2


                                  SCHEDULE 13G

-------------------------                                 ----------------------
CUSIP No. 090931106                                         Page 3 of 11 Pages
-------------------------                                 ----------------------
--------------------------------------------------------------------------------
1   NAME OF REPORTING PERSON:           Jeffrey K. Vogel
    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: [___________________]

--------------------------------------------------------------------------------
2    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a) [ ]
     (b) [ ]
--------------------------------------------------------------------------------
3    SEC USE ONLY

--------------------------------------------------------------------------------
4    CITIZENSHIP OR PLACE OR ORGANIZATION

     United States
--------------------------------------------------------------------------------

NUMBER OF SHARES             5    SOLE VOTING POWER           149,640
BENEFICIALLY OWNED           ---------------------------------------------------
BY EACH REPORTING            6    SHARED VOTING POWER         295,312(1)
PERSON WITH                  ---------------------------------------------------
                             7    SOLE DISPOSITIVE POWER      149,640
                             ---------------------------------------------------
                             8    SHARED DISPOSITIVE POWER    295,312(2)
--------------------------------------------------------------------------------
9    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     444,952(3)
--------------------------------------------------------------------------------
10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     (See Instructions)         N/A
--------------------------------------------------------------------------------
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     8.0% (4)
--------------------------------------------------------------------------------
12   TYPE OF REPORTING PERSON  (See Instructions)

     IN
--------------------------------------------------------------------------------

(1)  Mr. Vogel is the sole shareholder and President of Bio Management, which is
     the sole general partner of Bio Partners LP. Mr. Vogel thus has the power
     to vote these 295,312 shares of Common Stock owned by Bio Partners LP.

(2)  Mr. Vogel is the sole shareholder and President of Bio Management, which is
     the sole general partner of Bio Partners LP. Mr. Vogel thus has the power
     to dispose these 295,312 shares of Common Stock owned by Bio Partners LP.

(3)  Includes (i) 149,640 shares of Common Stock held directly by Jeffrey K.
     Vogel and (ii) 295,312 shares of Common Stock held by Bio Partners LP.

(4)  Calculated based on 5,535,216 shares of Biospecifics Technologies Corp.'s
     Common Stock outstanding as of November 9, 2005, as reported in its proxy
     statement on Schedule 14A filed with the Securities and Exchange Commission
     on December 2, 2005.

                                       3


                                  SCHEDULE 13G

-------------------------                                 ----------------------
CUSIP No. 090931106                                         Page 4 of 11 Pages
-------------------------                                 ----------------------

--------------------------------------------------------------------------------
1    NAME OF REPORTING PERSON:           Jon M. Vogel
     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: [___________________]

--------------------------------------------------------------------------------
2    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a) [ ]
     (b) [ ]
--------------------------------------------------------------------------------
3    SEC USE ONLY

--------------------------------------------------------------------------------
4    CITIZENSHIP OR PLACE OR ORGANIZATION

     United States
--------------------------------------------------------------------------------

NUMBER OF SHARES             5    SOLE VOTING POWER           149,566
BENEFICIALLY OWNED           ---------------------------------------------------
BY EACH REPORTING            6    SHARED VOTING POWER         0
PERSON WITH                  ---------------------------------------------------
                             7    SOLE DISPOSITIVE POWER      0
                             ---------------------------------------------------
                             8    SHARED DISPOSITIVE POWER    149,566(1)
--------------------------------------------------------------------------------
9    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     149,566
--------------------------------------------------------------------------------
10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     (See Instructions)         N/A
--------------------------------------------------------------------------------
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     2.7%(1)
--------------------------------------------------------------------------------
12   TYPE OF REPORTING PERSON  (See Instructions)

     IN
--------------------------------------------------------------------------------

(1)  Calculated based on 5,535,216 shares of Biospecifics Technologies Corp.'s
     Common Stock outstanding as of November 9, 2005, as reported in its proxy
     statement on Schedule 14A filed with the Securities and Exchange Commission
     on December 2, 2005.

                                       4


                                  SCHEDULE 13G

-------------------------                                 ----------------------
CUSIP No. 090931106                                         Page 5 of 11 Pages
-------------------------                                 ----------------------

--------------------------------------------------------------------------------
1    NAME OF REPORTING PERSON:           Sherman C. Vogel
     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: [___________________]

--------------------------------------------------------------------------------
2    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a) [ ]
     (b) [ ]
--------------------------------------------------------------------------------
3    SEC USE ONLY

--------------------------------------------------------------------------------
4    CITIZENSHIP OR PLACE OR ORGANIZATION

     United States
--------------------------------------------------------------------------------

NUMBER OF SHARES             5    SOLE VOTING POWER           148,107
BENEFICIALLY OWNED           ---------------------------------------------------
BY EACH REPORTING            6    SHARED VOTING POWER         0
PERSON WITH                  ---------------------------------------------------
                             7    SOLE DISPOSITIVE POWER      148,107
                             ---------------------------------------------------
                             8    SHARED DISPOSITIVE POWER    0
--------------------------------------------------------------------------------
9    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     148,107
--------------------------------------------------------------------------------
10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     (See Instructions)         N/A
--------------------------------------------------------------------------------
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     2.7% (1)
--------------------------------------------------------------------------------
12   TYPE OF REPORTING PERSON  (See Instructions)

     IN
--------------------------------------------------------------------------------

(1)  Calculated based on 5,535,216 shares of Biospecifics Technologies Corp.'s
     Common Stock outstanding as of November 9, 2005, as reported in its proxy
     statement on Schedule 14A filed with the Securities and Exchange Commission
     on December 2, 2005.

                                       5


Item 1.
         (a)      Name of Issuer:
                  --------------

                  Biospecifics Technologies Corp. ("Biospecifics")

         (b)      Address of Issuer's Principal Executive Offices:
                  -----------------------------------------------

                  35 Wilbur Street, Lynbrook, New York 11563

Item 2.
         (a)      Name of Persons Filing:
                  ----------------------

                  Bio Partners LP
                  Jeffrey K. Vogel
                  Jon M. Vogel
                  Sherman C. Vogel

         (b)      Address of Principal Business Office or, if none, Residence:
                  -----------------------------------------------------------

                  (i)    The address of each Bio Partners LP and Jeffrey K.
                         Vogel is:

                         1 Meadow Drive
                         Lawrence, NY 11559

                  (ii)   The address of Jon M. Vogel is:

                         17020 Brookwood Drive
                         Boca Raton, FL 33496

                  (iii)  The address of Sherman C. Vogel is:

                         7110 Melrose Castle Lane
                         Boca Raton, FL 33496

         (c)      Citizenship:
                  -----------

                  Bio Partners LP is a Delaware limited partnership.

                  Jeffrey K. Vogel, Jon M. Vogel and Sherman C. Vogel are each a
                  citizen of the United States.

         (d)      Title of Class of Securities:
                  ----------------------------

                  Common Stock, par value $.001 per share (the "Common Stock")

         (e)      CUSIP Number:
                  ------------

                  090931106

Item 3.

         This statement is not being filed pursuant to Rule 13d-1(b), or
13d-2(b) or (c).

                                       6


Item 4.  Ownership

         (a)      Amount beneficially owned:
                  -------------------------

                  Bio Partners LP beneficially owns 295,312 shares of
Biospecifics' Common Stock.

                  Jeffrey K. Vogel beneficially owns 444,952 shares of
Biospecifics' Common Stock, which includes (i) 149,640 shares of Common Stock
held directly by Jeffrey K. Vogel and (ii) 295,312 shares of Common Stock held
by Bio Partners LP.

                  Jon M. Vogel beneficially owns 149,566 shares of Biospecifics'
Common Stock.

                  Sherman C. Vogel beneficially owns 148,107 shares of
Biospecifics' Common Stock.

                  Together, the reporting persons beneficially own 742,625
shares of Biospecifics' Common Stock.

         (b)      Percent of class:
                  ----------------

                  Calculated based on 5,535,216 shares of Biospecifics
Technologies Corp.'s Common Stock outstanding as of November 9, 2005, as
reported in its proxy statement on Schedule 14A filed with the Securities and
Exchange Commission on December 2, 2005.

                  Bio Partners LP has beneficial ownership of 5.3% of all of the
outstanding shares of Biospecifics' Common Stock.

                  Jeffrey K. Vogel has beneficial ownership of 8.0% of all of
the outstanding shares of Biospecifics' Common Stock.

                  Jon M. Vogel has beneficial ownership of 2.7% of all of the
outstanding shares of Biospecifics' Common Stock.

                  Sherman C. Vogel has beneficial ownership of 2.7% of all of
the outstanding shares of Biospecifics' Common Stock.

                  Together, the reporting persons have beneficial ownership of
13.4% percent of all of the outstanding shares of Biospecifics' Common Stock.

         (c)      Number of shares as to which the person has:
                  -------------------------------------------

                  (i)   Sole power to vote or to direct the vote:
                        ----------------------------------------

                        Bio Partners LP has the sole power to vote or direct the
vote of 0 shares of Biospecifics' Common Stock.

                                       7


                        Jeffrey K. Vogel has the sole power to vote or direct
the vote of 149,640 shares of Biospecifics' Common Stock.

                        Jon M. Vogel has the sole power to vote or direct the
vote of 149,566 shares of Biospecifics' Common Stock.

                        Sherman C. Vogel has the sole power to vote or direct
the vote of 148,107 shares of Biospecifics' Common Stock.

                  (ii)  Shared power to vote or to direct the vote:
                        ------------------------------------------

                        Bio Partners LP has shared power to vote or direct the
vote of 295,312 shares of Biospecifics' Common Stock. Jeffrey K. Vogel is the
sole shareholder and President of Bio Management, Inc., a New York corporation
("Bio Management"), which is the sole general partner of Bio Partners LP. Mr.
Vogel thus has the power to vote or dispose of the 295,312 shares of
Biospecifics' Common Stock owned by Bio Partners LP.

                        Jeffrey K. Vogel has shared power to vote or direct the
vote of 295,312 shares of Biospecifics' Common Stock with Bio Partners LP.

                        Jon M. Vogel has shared power to vote or direct the vote
of 0 shares of Biospecifics' Common Stock.

                        Sherman C. Vogel has shared power to vote or direct the
vote of 0 shares of Biospecifics' Common Stock.

                  (iii) Sole power to dispose or to direct the disposition of:
                        -----------------------------------------------------

                        Bio Partners LP has the sole power to dispose or direct
the disposition of 0 shares of Biospecifics' Common Stock.

                        Jeffrey K. Vogel has the sole power to dispose or direct
the disposition of 149,640 shares of Biospecifics' Common Stock.

                        Jon M. Vogel has the sole power to dispose or direct the
disposition of 149,566 shares of Biospecifics' Common Stock.

                        Sherman C. Vogel has the sole power to dispose or direct
the disposition of 148,107 shares of Biospecifics' Common Stock.

                  (iv)  Shared power to dispose or to direct the disposition of:
                        -------------------------------------------------------

                        Bio Partners LP has the shared power to dispose or
direct the disposition of 295,312 shares of Biospecifics' Common Stock. Jeffrey
K. Vogel is the sole shareholder and President of Bio Management, the sole
general partner of Bio Partners LP. Mr. Vogel thus has the power to vote or
dispose of the 295,312 shares of Common Stock owned by Bio Partners LP.

                                       8


                        Jeffrey K. Vogel has the shared power to dispose or
direct the disposition of 295,312 shares of Biospecifics' Common Stock owned by
Bio Partners LP.

                        Jon M. Vogel has the shared power to dispose or direct
the disposition of 0 shares of Biospecifics' Common Stock.

                        Sherman C. Vogel has the shared power to dispose or
direct the disposition of 0 shares of Biospecifics' Common Stock.

Item 5.  Ownership of Five Percent or Less of a Class

         Not Applicable.

Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

         Not applicable.

Item 7.  Identification and Classification of the Subsidiary Which Acquired the
         Security Being Reported on By the Parent Holding Company or Control
         Person

         Not applicable.

Item 8.  Identification and Classification of Members of the Group

         Not Applicable

Item 9.  Notice of Dissolution of Group

         Not Applicable

Item 10. Certification

         (b) This Schedule 13G Amendment is being filed pursuant to Rule
13d-1(c):

         By signing below we certify that, to the best of our knowledge and
belief, the securities referred to above were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.


                                       9


                                    SIGNATURE

         After reasonable inquiry and to the best of each undersigned's
knowledge and belief, the undersigned hereby certify that the information set
forth in this Statement is true, complete and correct.

January 10, 2007


                                       BIO PARTNERS LP

                                       By: Bio Management, Inc., its sole
                                           general partner

                                       By: /s/ JEFFREY K. VOGEL
                                           -------------------------------------
                                           Name:  Jeffrey K. Vogel
                                           Title: President



                                           /s/ JEFFREY K. VOGEL
                                           -------------------------------------
                                           Jeffrey K. Vogel


                                           /s/ JON M. VOGEL
                                           -------------------------------------
                                           Jon M. Vogel


                                           /s/ SHERMAN C. VOGEL
                                           -------------------------------------
                                           Sherman C. Vogel


                                       10

                                    EXHIBIT A

                             JOINT FILING AGREEMENT


         The undersigned agree that this Amendment No. 3 to Schedule 13G filed
herewith relating to the shares of common stock of Biospecifics Technologies
Corp. is filed jointly on behalf of each of the undersigned pursuant to Rule
13d-1(k) under the Exchange Act.


January 10, 2007


                                       BIO PARTNERS LP

                                       By: Bio Management, Inc., its sole
                                           general partner

                                       By: /s/ JEFFREY K. VOGEL
                                           -------------------------------------
                                           Name:  Jeffrey K. Vogel
                                           Title: President


                                           /s/ JEFFREY K. VOGEL
                                           -------------------------------------
                                           Jeffrey K. Vogel


                                           /s/ JON M. VOGEL
                                           -------------------------------------
                                           Jon M. Vogel


                                           /s/ SHERMAN C. VOGEL
                                           -------------------------------------
                                           Sherman C. Vogel



                                       11